Targeted Antibiotic Therapy for Pneumonia
Trial Summary
What is the purpose of this trial?
The purpose of this study is to reduce the exposure of broad-spectrum antimicrobials by optimizing the rapid detection of CAP pathogens and improving rates of de-escalation following negative cultures. To accomplish this, we will perform a 3-year, pragmatic, multicenter 2 X 2 factorial cluster randomized controlled trial with four arms: a) rapid diagnostic testing b) pharmacist-led de-escalation c) rapid diagnostic testing + pharmacist-led de-escalation and d) usual care
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug Meropenem-Vaborbactam for treating pneumonia?
Meropenem-Vaborbactam has shown effectiveness in treating infections caused by carbapenem-resistant Enterobacteriaceae (CRE), particularly those involving Klebsiella pneumoniae, which is a common cause of pneumonia. It has been demonstrated to be effective in treating complicated urinary tract infections and other invasive infections, suggesting its potential usefulness in treating pneumonia caused by similar resistant bacteria.12345
How does targeted antibiotic therapy for pneumonia differ from other treatments?
Targeted antibiotic therapy for pneumonia is unique because it focuses on using specific antibiotics that are effective against multidrug-resistant bacteria, like Pseudomonas aeruginosa, which are difficult to treat with standard antibiotics. This approach may involve newer antibiotics such as ceftolozane-tazobactam and ceftazidime-avibactam, which are designed to combat resistant strains more effectively.678910
Research Team
Michael Rothberg, M.D.
Principal Investigator
The Cleveland Clinic
Eligibility Criteria
This trial is for adults over 18 with pneumonia, admitted to a participating hospital without intensive care in the first 24 hours, not on comfort care only, without cystic fibrosis or recent discharge from acute care. It excludes those known to have a specific pathogen causing their illness.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive rapid diagnostic testing and/or pharmacist-led de-escalation for community-acquired pneumonia
Follow-up
Participants are monitored for safety and effectiveness after treatment, including infection with resistant organisms and 30-day readmission
Treatment Details
Interventions
- Pharmacist-led de-escalation
- Rapid Diagnostic Testing
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Cleveland Clinic
Lead Sponsor